John Gordon
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
John Gordon has a total of 56 co-authors. Here are the top co-authors by number of shared publications:
Michelle J. Holder
University of Birmingham
6 shared publicationsNicholas M. Barnes
Cellular and Molecular Neuropharmacology Research Group, Clinical and Experimental Medicine, The Medical School, Birmingham, UK
6 shared publicationsAnita Challa
University of Birmingham
4 shared publicationsAnita Chamba
University of Birmingham
4 shared publicationsChristopher D. Gregory
From the MRC Centre for Immune Regulation and the Institute for Cancer Studies, The University of Birmingham, Birmingham, United Kingdom; School of Biomedical Sciences, The University of Nottingham, Nottingham, United Kingdom; Institute of Cell, Animal and Population Biology, University of Edinburgh, United Kingdom; Immunex Corporation, Seattle, WA; Department of Immunology, MD Anderson Cancer Center, Houston, TX
4 shared publicationsJohn D. Pound
From the MRC Centre for Immune Regulation and the Institute for Cancer Studies, The University of Birmingham, Birmingham, United Kingdom; School of Biomedical Sciences, The University of Nottingham, Nottingham, United Kingdom; Institute of Cell, Animal and Population Biology, University of Edinburgh, United Kingdom; Immunex Corporation, Seattle, WA; Department of Immunology, MD Anderson Cancer Center, Houston, TX
4 shared publications
Latest Publications
- Open Access
- 1 January 2017
- Published by Elsevier in International Immunopharmacology
- Vol. 42, 108-114
Inosine Acedoben Dimepranol promotes an early and sustained increase in the natural killer cell component of circulating lymphocytes: A clinical trial supporting anti-viral indications
- 1 January 2017
- Published by Elsevier in International Immunopharmacology
- Vol. 42, 108-114
Open AccessInosine Acedoben Dimepranol promotes an early and sustained increase in the natural killer cell component of circulating lymphocytes: A clinical trial supporting anti-viral indications
- 1 February 2012
- Published by Elsevier in Leukemia Research
- Vol. 36 (2) , 245-249
Evidence for functional trace amine associated receptor-1 in normal and malignant B cells
- 1 February 2012
- Published by Elsevier in Leukemia Research
- Vol. 36 (2) , 245-249
Evidence for functional trace amine associated receptor-1 in normal and malignant B cells
- 18 August 2011
- Published by Springer Nature in Investigational New Drugs
- Vol. 30 (4) , 1471-1483
Enhancing the anti-lymphoma potential of 3,4-methylenedioxymethamphetamine (‘ecstasy’) through iterative chemical redesign: mechanisms and pathways to cell death
While 3,4-methylenedioxymethamphetamine (MDMA/‘ecstasy’) is cytostatic towards lymphoma cells in vitro, the concentrations required militate against its translation directly to a therapeutic in vivo. The possibility of ‘redesigning the designer drug’, separating desired anti-lymphoma activity from unwanted psychoactivity and neurotoxicity, was therefore mooted. From an initial analysis of MDMA analogues synthesized with a modified α-substituent, it was found that incorporating a phenyl group increased potency against sensitive, Bcl-2-deplete, Burkitt’s lymphoma (BL) cells 10-fold relative to MDMA. From this lead, related analogs were synthesized with the ‘best’ compounds (containing 1- and 2-naphthyl and para-biphenyl substituents) some 100-fold more potent than MDMA versus the BL target. When assessed against derived lines from a diversity of B-cell tumors MDMA analogues were seen to impact the broad spectrum of malignancy. Expressing a BCL2 transgene in BL cells afforded only scant protection against the analogues and across the malignancies no significant correlation between constitutive Bcl-2 levels and sensitivity to compounds was observed. Bcl-2-deplete cells displayed hallmarks of apoptotic death in response to the analogues while BCL2 overexpressing equivalents died in a caspase-3-independent manner. Despite lymphoma cells expressing monoamine transporters, their pharmacological blockade failed to reverse the anti-lymphoma actions of the analogues studied. Neither did reactive oxygen species account for ensuing cell death. Enhanced cytotoxic performance did however track with predicted lipophilicity amongst the designed compounds. In conclusion, MDMA analogues have been discovered with enhanced cytotoxic efficacy against lymphoma subtypes amongst which high-level Bcl-2—often a barrier to drug performance for this indication—fails to protect.
- 18 August 2011
- Published by Springer Nature in Investigational New Drugs
- Vol. 30 (4) , 1471-1483
Enhancing the anti-lymphoma potential of 3,4-methylenedioxymethamphetamine (‘ecstasy’) through iterative chemical redesign: mechanisms and pathways to cell death
While 3,4-methylenedioxymethamphetamine (MDMA/‘ecstasy’) is cytostatic towards lymphoma cells in vitro, the concentrations required militate against its translation directly to a therapeutic in vivo. The possibility of ‘redesigning the designer drug’, separating desired anti-lymphoma activity from unwanted psychoactivity and neurotoxicity, was therefore mooted. From an initial analysis of MDMA analogues synthesized with a modified α-substituent, it was found that incorporating a phenyl group increased potency against sensitive, Bcl-2-deplete, Burkitt’s lymphoma (BL) cells 10-fold relative to MDMA. From this lead, related analogs were synthesized with the ‘best’ compounds (containing 1- and 2-naphthyl and para-biphenyl substituents) some 100-fold more potent than MDMA versus the BL target. When assessed against derived lines from a diversity of B-cell tumors MDMA analogues were seen to impact the broad spectrum of malignancy. Expressing a BCL2 transgene in BL cells afforded only scant protection against the analogues and across the malignancies no significant correlation between constitutive Bcl-2 levels and sensitivity to compounds was observed. Bcl-2-deplete cells displayed hallmarks of apoptotic death in response to the analogues while BCL2 overexpressing equivalents died in a caspase-3-independent manner. Despite lymphoma cells expressing monoamine transporters, their pharmacological blockade failed to reverse the anti-lymphoma actions of the analogues studied. Neither did reactive oxygen species account for ensuing cell death. Enhanced cytotoxic performance did however track with predicted lipophilicity amongst the designed compounds. In conclusion, MDMA analogues have been discovered with enhanced cytotoxic efficacy against lymphoma subtypes amongst which high-level Bcl-2—often a barrier to drug performance for this indication—fails to protect.
- 30 June 2008
- Published by Elsevier in Seminars in Cancer Biology
- Vol. 18 (3) , 149
Neuro-immuno-endocrine considerations for cancer development and therapeutics
- 30 June 2008
- Published by Elsevier in Seminars in Cancer Biology
- Vol. 18 (3) , 149
Neuro-immuno-endocrine considerations for cancer development and therapeutics
- 5 September 2006
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 103 (36) , 13485-13490
Dopamine targets cycling B cells independent of receptors/transporter for oxidative attack: Implications for non-Hodgkin’s lymphoma
Human B lymphocytes and derived lines from a spectrum of B cell malignancy were studied for expression of dopaminergic pathway components and for their cytostatic response to the catecholamine and related, potentially therapeutic compounds. Proliferating normal lymphocytes and dividing malignant clones rapidly arrested on exposure to dopamine in the low (≤10 μM) micromolar range. The antiparkinsonian drugs l -DOPA and apomorphine (particularly) were similarly antiproliferative. With the exception of D4, dopamine receptors D1–D5 were variably expressed among normal and neoplastic B cell populations, as was the dopamine transporter. Transcripts for D1 and D2 were frequently found, whereas D3 and D5 revealed restricted expression; dopamine transporter was detected in most cases. Nevertheless, pharmacological analysis disclosed that dopamine targeted cycling B cells independent of these structures. Rather, oxidative stress constituted the primary mechanism: the catecholamine’s actions being mimicked by hydrogen peroxide and reversed by exogenous catalase, and evidence for the intracellular redox protein thioredoxin contributing protection. Among proliferating clones, growth arrest was accompanied by cell death in populations deplete in antiapoptotic Bcl-2: resting lymphocytes escaping low micromolar dopamine toxicity. Dysregulated bcl-2 expression, although preventing oxidative-induced caspase-dependent apoptosis, by itself conferred only minor protection against dopamine cytostasis. The selective impact of dopamine on lymphocytes that are in active cycle indicates an axis for therapeutic intervention not only in B cell neoplasia but also in lymphoproliferative disturbances generally. Rational tailoring of drug delivery systems already in development for Parkinson’s disease could provide ideal vehicles for carrying the oxidative hit directly to the target populations.
- 5 September 2006
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 103 (36) , 13485-13490
Dopamine targets cycling B cells independent of receptors/transporter for oxidative attack: Implications for non-Hodgkin’s lymphoma
Human B lymphocytes and derived lines from a spectrum of B cell malignancy were studied for expression of dopaminergic pathway components and for their cytostatic response to the catecholamine and related, potentially therapeutic compounds. Proliferating normal lymphocytes and dividing malignant clones rapidly arrested on exposure to dopamine in the low (≤10 μM) micromolar range. The antiparkinsonian drugs l -DOPA and apomorphine (particularly) were similarly antiproliferative. With the exception of D4, dopamine receptors D1–D5 were variably expressed among normal and neoplastic B cell populations, as was the dopamine transporter. Transcripts for D1 and D2 were frequently found, whereas D3 and D5 revealed restricted expression; dopamine transporter was detected in most cases. Nevertheless, pharmacological analysis disclosed that dopamine targeted cycling B cells independent of these structures. Rather, oxidative stress constituted the primary mechanism: the catecholamine’s actions being mimicked by hydrogen peroxide and reversed by exogenous catalase, and evidence for the intracellular redox protein thioredoxin contributing protection. Among proliferating clones, growth arrest was accompanied by cell death in populations deplete in antiapoptotic Bcl-2: resting lymphocytes escaping low micromolar dopamine toxicity. Dysregulated bcl-2 expression, although preventing oxidative-induced caspase-dependent apoptosis, by itself conferred only minor protection against dopamine cytostasis. The selective impact of dopamine on lymphocytes that are in active cycle indicates an axis for therapeutic intervention not only in B cell neoplasia but also in lymphoproliferative disturbances generally. Rational tailoring of drug delivery systems already in development for Parkinson’s disease could provide ideal vehicles for carrying the oxidative hit directly to the target populations.
- 9 June 2005
- Published by Wiley in Immunology
- Vol. 115 (3) , 289-295
Close encounters of the monoamine kind: immune cells betray their nervous disposition
Summary: Here we review the evidence for immune cells expressing multiple components of the serotonergic and dopaminergic systems that are more commonly associated with the central nervous system (CNS). We discuss where and how peripheral encounters with these biogenic monoamines occur and posit reasons as to why the immune system would wish to deploy these pathways. A full taxonomy of serotonergic and dopaminergic constituents and their workings in component cells of the immune system should facilitate the formulation of novel therapeutic approaches in diseases characterized by immune dysfunction and potentially provide a range of surrogate peripheral markers for registering and monitoring disturbances within the CNS.
- 9 June 2005
- Published by Wiley in Immunology
- Vol. 115 (3) , 289-295
Close encounters of the monoamine kind: immune cells betray their nervous disposition
Summary: Here we review the evidence for immune cells expressing multiple components of the serotonergic and dopaminergic systems that are more commonly associated with the central nervous system (CNS). We discuss where and how peripheral encounters with these biogenic monoamines occur and posit reasons as to why the immune system would wish to deploy these pathways. A full taxonomy of serotonergic and dopaminergic constituents and their workings in component cells of the immune system should facilitate the formulation of novel therapeutic approaches in diseases characterized by immune dysfunction and potentially provide a range of surrogate peripheral markers for registering and monitoring disturbances within the CNS.
- Open Access
- 3 May 2005
- Published by Wiley in The FASEB Journal
- Vol. 19 (9) , 1187-1189
The serotonin transporter (SLC6A4) is present in B‐cell clones of diverse malignant origin: probing a potential antitumor target for psychotropics
Following our previous description of the serotonin transporter (SERT) acting as a conduit to 5‐hydroxytryptamine (5‐HT)‐mediated apoptosis, specifically in Burkitt's lymphoma, we now detail its expression among a broad spectrum of B cell malignancy, while exploring additional SERT substrates for potential therapeutic activity. SERT was readily detected in derived B cell lines with origins as diverse as B cell precursor acute lymphoblastic leukemia, mantle cell lymphoma, diffuse large B cell lymphoma, and multiple myeloma. Concentration and timecourse kinetics for the antiproliferative and proapoptotic activities of the amphetamine derivatives fenfluramine (an appetite suppressant) and 3,4‐methylenedioxymethamphetamine (MDMA; “Ecstasy”) revealed them as being similar to the endogenous indoleamine. A tricyclic antidepressant, clomipramine, instead mirrored the behavior of the selective serotonin reuptake inhibitor fluoxetine, both being effective in the low micromolar range. A majority of neoplastic clones were sensitive to one or more of the serotonergic compounds. Dysregulated bcl‐2 expression, either by t(14;18)(q32;q21) translocation or its introduction as a constitutively active transgene, provided protection from proapoptotic but not antiproliferative outcomes. These data indicate a potential for SERT as a novel anti‐tumor target for amphetamine analogs, while evidence is presented that the seemingly more promising antidepressants are likely impacting malignant B cells independently of the transporter itself.
- 3 May 2005
- Published by Wiley in The FASEB Journal
- Vol. 19 (9) , 1187-1189
Open AccessThe serotonin transporter (SLC6A4) is present in B‐cell clones of diverse malignant origin: probing a potential antitumor target for psychotropics
Following our previous description of the serotonin transporter (SERT) acting as a conduit to 5‐hydroxytryptamine (5‐HT)‐mediated apoptosis, specifically in Burkitt's lymphoma, we now detail its expression among a broad spectrum of B cell malignancy, while exploring additional SERT substrates for potential therapeutic activity. SERT was readily detected in derived B cell lines with origins as diverse as B cell precursor acute lymphoblastic leukemia, mantle cell lymphoma, diffuse large B cell lymphoma, and multiple myeloma. Concentration and timecourse kinetics for the antiproliferative and proapoptotic activities of the amphetamine derivatives fenfluramine (an appetite suppressant) and 3,4‐methylenedioxymethamphetamine (MDMA; “Ecstasy”) revealed them as being similar to the endogenous indoleamine. A tricyclic antidepressant, clomipramine, instead mirrored the behavior of the selective serotonin reuptake inhibitor fluoxetine, both being effective in the low micromolar range. A majority of neoplastic clones were sensitive to one or more of the serotonergic compounds. Dysregulated bcl‐2 expression, either by t(14;18)(q32;q21) translocation or its introduction as a constitutively active transgene, provided protection from proapoptotic but not antiproliferative outcomes. These data indicate a potential for SERT as a novel anti‐tumor target for amphetamine analogs, while evidence is presented that the seemingly more promising antidepressants are likely impacting malignant B cells independently of the transporter itself.
- 30 November 2003
- Published by Elsevier in Trends in Immunology
- Vol. 24 (11) , 582-583
Response to Cosentino et al.: No NAT yet
- 30 November 2003
- Published by Elsevier in Trends in Immunology
- Vol. 24 (11) , 582-583
Response to Cosentino et al.: No NAT yet
- 1 August 2003
- Published by Elsevier in Trends in Immunology
- Vol. 24 (8) , 438-443
Lymphocytes transport serotonin and dopamine: agony or ecstasy?
- 1 August 2003
- Published by Elsevier in Trends in Immunology
- Vol. 24 (8) , 438-443
Lymphocytes transport serotonin and dopamine: agony or ecstasy?